These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
JAK1 Manuscript end.pdf (1.31 MB)

The Potential of JAK/STAT Pathway Inhibition as a New Treatment Strategy to Control Cytokine Release Syndrome in COVID-19

submitted on 14.09.2020, 09:12 and posted on 15.09.2020, 09:33 by Mohammad Seyedhamzeh, Hazha Omar Othman, Ali aghajani Sharivar, Fatemeh Aliabadi, Mehdi Shafiee Ardestani, Hamidreza Pazoki-Toroudi
COVID-19, a pandemic affecting virus, which is caused by the current SARS-CoV2 coronavirus. The present research is performed on anti virus and immune-modulating therapies. Cytokine storms are the toxic drivers and mortality caused by various human viral infections. In addition, the intensity was linked to an elevated risk of acute respiratory failure, myocardial injury, and mortality in SARS-CoV-2-infected patients. The Janus kinase (JAK) therapeutic inhibitor class showed significant clinical benefits in anti-inflammatory and anti-viral effects. Among them, filgotinib has been approved as an active JAK inhibitor by decreasing biomarkers with main immune reaction functions and markers supporting matrix-degradation, angiogenesis, leukocyte adhesion, and recruitment in both research trials. In this study, we tried to get an insight into the choice of this drug in controlling the jack, to treat Covid 19 using drug design methods will be discussed.


Email Address of Submitting Author


Iran University of Medical Sciences



ORCID For Submitting Author


Declaration of Conflict of Interest

There is no conflict of interest